Lowenthal Richard E 4

4 · ARS Pharmaceuticals, Inc. · Filed Dec 9, 2024

Form 4

Period: 2024-12-06

DirectorPRESIDENT AND CEO10% Owner

Transactions

Exercise/Conversion
Stock Option (right to buy)
2024-12-06−11,876→ 1,088,124 total
Exercise: $8.42Exp: 2033-01-02→ Common Stock (11,876 underlying)
Exercise/Conversion
Stock Option (right to buy)
2024-12-06−13,789→ 20,684 total(indirect: By Spouse)
Exercise: $1.44Exp: 2031-12-13→ Common Stock (13,789 underlying)
Exercise/Conversion
Stock Option (right to buy)
2024-12-06−11,876→ 338,124 total(indirect: By Spouse)
Exercise: $8.42Exp: 2033-01-02→ Common Stock (11,876 underlying)
Exercise/Conversion
Common Stock
2024-12-06$1.44/sh+13,789$19,856→ 3,421,636 total(indirect: By Spouse)
Exercise/Conversion
Common Stock
2024-12-06$8.42/sh+11,876$99,996→ 4,327,189 total
Exercise/Conversion
Common Stock
2024-12-06$8.42/sh+11,876$99,996→ 3,433,512 total(indirect: By Spouse)

Holdings

Footnotes (4)

[F1]The Reporting Person is trustee of the trust.
[F2]The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.
[F3]The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
[F4]25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

Documents

1 file